Characteristics of the studies included in the meta-analysis
| Study (author/year) | Study type | Number of patients (isatuximab group/control) | Cancer type | Drug (dose & duration) | Primary outcome measure |
|---|---|---|---|---|---|
| ICARIA-MM [8]Attal et al. [13], 2019 | Randomized, multicenter, open-label, phase 3 trial | 154/153 | Relapsed and refractory MM (RRMM) | Isatuximab (10 mg/kg intravenously) + pomalidomide (4 mg orally) + dexamethasone (40 mg orally or intravenously), in 28-day cycles. | Progression-free survival |
| IKEMA [9]Moreau et al. [14], 2021 | Multicenter, open-label, randomized, phase 3 trial | 179/123 | RRMM | Isatuximab (10 mg/kg intravenously weekly for the first 4 weeks, then every 2 weeks) + carfilzomib (20 mg/m2 initially, followed by 56 mg/m2) + dexamethasone (20 mg orally or intravenously). | Progression-free survival |
| IMROZ [10]Facon et al. [15], 2024 | Phase 3, open-label, multicenter, randomized trial | 265/181 | Newly diagnosed MM, ineligible for transplantation | Isatuximab (10 mg/kg intravenously) + bortezomib (1.3 mg/m2 subcutaneously) + lenalidomide (25 mg orally) + dexamethasone (20 mg orally or intravenously) in 6-week cycles. | Progression-free survival |
| GMMG-HD7 [11]Goldschmidt et al. [16], 2022 | Phase 3, open-label, multicenter, randomized, active-controlled trial | 331/329 | Newly diagnosed, transplantation-eligible MM | Isatuximab (10 mg/kg intravenously) + lenalidomide (25 mg orally) + bortezomib (1.3 mg/m2 subcutaneously) + dexamethasone (20 mg orally) for 42-day cycles. | Minimal residual disease negativity |
MM: multiple myeloma
